Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys
- PMID: 16407771
- DOI: 10.1097/01.wnr.0000198952.38563.05
Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys
Erratum in
- Neuroreport. 2006 Mar 20;17(4):453
Abstract
The present report describes for the first time, the stability of recombinant adeno-associated virus serotype 2 (AAV2) human aromatic L-amino acid decarboxylase (hAADC) gene transfer after 3-year survival time in a non-human primate model of Parkinson's disease. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned monkeys were treated with six injections of 30 microl/site of AAV2-hAADC at a concentration of 2 x 10(12) vg/ml into the caudate and putamen. Stereological analysis revealed a 46.6% increase in the total number of AAV2-hAADC-transduced cells in the striatum between 8 weeks and 3 years after gene transfer survival time. In the 8-week animals, the distribution of the AADC+ cells was dispersed and heterogeneous, whereas in the 3-year animals it was widespread and homogenous. Confocal analysis demonstrated that approximately 85% of the AADC+ cells were neuronal nuclei immunoreactive.
Similar articles
-
Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.PLoS One. 2015 Apr 10;10(4):e0122708. doi: 10.1371/journal.pone.0122708. eCollection 2015. PLoS One. 2015. PMID: 25860990 Free PMC article.
-
Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.PLoS One. 2017 Feb 6;12(2):e0169965. doi: 10.1371/journal.pone.0169965. eCollection 2017. PLoS One. 2017. PMID: 28166239 Free PMC article.
-
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.Mol Ther. 2010 Aug;18(8):1458-61. doi: 10.1038/mt.2010.106. Epub 2010 Jun 8. Mol Ther. 2010. PMID: 20531394 Free PMC article.
-
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.Exp Neurol. 2000 Jul;164(1):2-14. doi: 10.1006/exnr.2000.7408. Exp Neurol. 2000. PMID: 10877910
-
[AAV vector-mediated gene transfer and its application to the nervous system].Rinsho Shinkeigaku. 2003 Nov;43(11):835-8. Rinsho Shinkeigaku. 2003. PMID: 15152479 Review. Japanese.
Cited by
-
Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat.J Gene Med. 2010 Apr;12(4):385-98. doi: 10.1002/jgm.1449. J Gene Med. 2010. PMID: 20352617 Free PMC article.
-
Neurosurgical gene therapy for central nervous system diseases.Neurotherapeutics. 2024 Jul;21(4):e00434. doi: 10.1016/j.neurot.2024.e00434. Epub 2024 Aug 26. Neurotherapeutics. 2024. PMID: 39191071 Free PMC article. Review.
-
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.Stereotact Funct Neurosurg. 2011;89(3):141-51. doi: 10.1159/000323544. Epub 2011 Apr 14. Stereotact Funct Neurosurg. 2011. PMID: 21494065 Free PMC article.
-
Gene Therapy for Parkinson's Disease, An Update.J Parkinsons Dis. 2018;8(2):195-215. doi: 10.3233/JPD-181331. J Parkinsons Dis. 2018. PMID: 29710735 Free PMC article. Review.
-
Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.Hum Gene Ther. 2012 Feb;23(2):210-7. doi: 10.1089/hum.2011.162. Epub 2012 Jan 26. Hum Gene Ther. 2012. PMID: 22017504 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources